NCT06055075 - A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

July 8, 2025

Study Completion Date

July 8, 2025

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG

Forimtamig

Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.

DRUG

Carfilzomib

Carfilzomib will be administered via IV infusion in combination with forimtamig.

DRUG

Daratumumab

Daratumumab will be administered via SC injection in combination with forimtamig.

Trial Locations (7)

1010

New Zealand Clinical Research - Auckland, Auckland

4102

Princess Alexandra Hospital Woolloongabba, Woolloongabba

5000

Royal Adelaide Hospital, Adelaide

20089

Istituto Clinico Humanitas, Rozzano

31008

Clinica Universitaria de Navarra, Pamplona

L8V 5C2

Hamilton Health Sciences, Hamilton

06591

Seoul St Mary's Hospital, Seoul

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY